165 related articles for article (PubMed ID: 26656559)
1. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
[TBL] [Abstract][Full Text] [Related]
2. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
4. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
[TBL] [Abstract][Full Text] [Related]
5. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
6. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
7. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
8. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2.
Mintz A; Gibo DM; Madhankumar AB; Cladel NM; Christensen ND; Debinski W
Cancer Biother Radiopharm; 2008 Oct; 23(5):581-9. PubMed ID: 18976118
[TBL] [Abstract][Full Text] [Related]
9. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma.
Ulasov IV; Tyler MA; Han Y; Glasgow JN; Lesniak MS
Hum Gene Ther; 2007 Feb; 18(2):118-29. PubMed ID: 17328684
[TBL] [Abstract][Full Text] [Related]
10. Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy.
Stern LA; Gholamin S; Moraga I; Yang X; Saravanakumar S; Cohen JR; Starr R; Aguilar B; Salvary V; Hibbard JC; Kalbasi A; Shepphird JK; O'Hearn J; Garcia KC; Brown CE
Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2112006119. PubMed ID: 35939683
[TBL] [Abstract][Full Text] [Related]
11. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
12. An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma.
Shi J; Hou S; Huang J; Wang S; Huan W; Huang C; Liu X; Jiang R; Qian W; Lu J; Wang X; Shi W; Huang R; Chen J
Nanoscale; 2017 Jul; 9(26):8970-8981. PubMed ID: 28443896
[TBL] [Abstract][Full Text] [Related]
13. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.
Bernardi RJ; Lowery AR; Thompson PA; Blaney SM; West JL
J Neurooncol; 2008 Jan; 86(2):165-72. PubMed ID: 17805488
[TBL] [Abstract][Full Text] [Related]
14. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.
Gupta P; Jiang ZK; Yang B; Manzuk L; Rosfjord E; Yao J; Lemon L; Noorbehesht K; David J; Puthenveetil S; Casavant JM; Muszynska E; Li F; Leal M; Sapra P; Giddabasappa A
MAbs; 2021; 13(1):1958662. PubMed ID: 34347577
[TBL] [Abstract][Full Text] [Related]
15. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
16. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Thaci B; Brown CE; Binello E; Werbaneth K; Sampath P; Sengupta S
Neuro Oncol; 2014 Oct; 16(10):1304-12. PubMed ID: 24723564
[TBL] [Abstract][Full Text] [Related]
17. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
18. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
Sengupta S; Thaci B; Crawford AC; Sampath P
Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]